Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001209191-17-050363)

Filing Details

Accession Number:
0001209191-17-050363
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-08-28 14:39:03
Reporting Period:
2017-08-24
Accepted Time:
2017-08-28 13:39:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1571498 Epizyme Inc. EPZM Pharmaceutical Preparations (2834) 261349956
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1619052 Tai-Ching Peter Ho C/O Epizyme, Inc.
400 Technology Square
Cambridge MA 02139		 Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Acquisiton 2017-08-24 15,000 $8.98 22,228 No 4 M Direct
Common Stock, Par Value $0.0001 Disposition 2017-08-24 15,000 $15.68 7,228 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2017-08-24 15,000 $0.00 15,000 $8.98
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
25,950 2026-02-07 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, Par Value $0.0001 1,000 Indirect By Trust
Common Stock, Par Value $0.0001 1,000 Indirect By Trust
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.5 per share to $15.8 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. These shares are held in a brokerage account jointly owned by the reporting person and his spouse.
  3. These shares are held in trust for the benefit of the reporting person's child. The reporting person's spouse is a trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  4. The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  5. This option is fully vested.